Pharmacokinetics and Toxicology of the Neuroprotective e,e,e-Methanofullerene(60)-63-tris Malonic Acid [C3] in Mice and Primates
暂无分享,去创建一个
J. Perlmutter | L. Dugan | Joshua I. Hardt | S. Chakraborty | Ling-Rong Wei | C. J. Smith | Kevin L. Quick
[1] Shery Jacob,et al. A simple practice guide for dose conversion between animals and human , 2016, Journal of basic and clinical pharmacy.
[2] John Polich,et al. Carboxyfullerene neuroprotection postinjury in Parkinsonian nonhuman primates , 2014, Annals of neurology.
[3] R. Mach,et al. No Differential Regulation of Dopamine Transporter (DAT) and Vesicular Monoamine Transporter 2 (VMAT2) Binding in a Primate Model of Parkinson Disease , 2012, PloS one.
[4] C. Xiong,et al. A carboxyfullerene SOD mimetic improves cognition and extends the lifespan of mice , 2008, Neurobiology of Aging.
[5] C. Xiong,et al. Gender differences in free radical homeostasis during aging: shorter‐lived female C57BL6 mice have increased oxidative stress , 2006, Aging cell.
[6] C. Epstein,et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. , 2004, Free radical biology & medicine.
[7] L. Ho,et al. Local carboxyfullerene protects cortical infarction in rat brain , 2002, Neuroscience Research.
[8] K. O’Malley,et al. Fullerene-based antioxidants and neurodegenerative disorders. , 2001, Parkinsonism & related disorders.
[9] L. Dugan,et al. Superoxide stress identifies neurons at risk in a model of ataxia‐telangiectasia , 2001, Annals of neurology.
[10] A. Majid,et al. Differences in Vulnerability to Permanent Focal Cerebral Ischemia Among 3 Common Mouse Strains , 2000, Stroke.
[11] S. Kennel,et al. In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[12] K. O’Malley,et al. Distinct Mechanisms Underlie Neurotoxin-Mediated Cell Death in Cultured Dopaminergic Neurons , 1999, The Journal of Neuroscience.
[13] B. Erlanger,et al. Antigenicity of fullerenes: antibodies specific for fullerenes and their characteristics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[14] C. Chou,et al. Blockage of apoptotic signaling of transforming growth factor-beta in human hepatoma cells by carboxyfullerene. , 1998, European journal of biochemistry.
[15] Shen,et al. Carboxyfullerenes as neuroprotective agents. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] F. Wudl,et al. Pharmacokinetics of a water-soluble fullerene in rats , 1996, Antimicrobial agents and chemotherapy.
[17] D. Choi,et al. Buckminsterfullerenol Free Radical Scavengers Reduce Excitotoxic and Apoptotic Death of Cultured Cortical Neurons , 1996, Neurobiology of Disease.
[18] E. Nakamura,et al. In vivo biological behavior of a water-miscible fullerene: 14C labeling, absorption, distribution, excretion and acute toxicity. , 1995, Chemistry & biology.
[19] Y. Nagai,et al. Comparative haematological and plasma chemistry values in purpose-bred squirrel, cynomolgus and rhesus monkeys , 1994, Comparative Haematology International.
[20] H. L. Wiener,et al. Separation and determination of sertraline and its metabolite, desmethylsertraline, in mouse cerebral cortex by reversed-phase high-performance liquid chromatography. , 1990, Journal of chromatography.
[21] L. Tremaine,et al. Characterization of a carbamic acid ester glucuronide of the secondary amine sertraline. , 1989, Drug metabolism and disposition: the biological fate of chemicals.